Biomay Offers GMP Allergens off the Shelf (Feb. 11 2009)

Biomay announced to offer GMP-grade allergens as active pharmaceutical ingredients off the shelf.

Biomay thereby addresses companies and academic allergists requiring recombinant allergens for commercial or investigator-driven clinical trials. The material, which is a surplus of own clinical trials, is manufactured andquality-released by Biomay. It is going to be shipped to clients in a frozen state on dry ice, with a temperature logger. By considering the client´s individual needs, the shipment can be accompanied with the respective certificates of analysis and compliance, stability documentation and technical reports.

“We are convinced there is a market for short-term available GMP allergens. Thisbusiness segment will enable us to offer pharmaceutical-grade material at a significantly lower price  compared to common contract manufactured products,” states Dr. Ursula Baumgartner-Durchschlag, Quality Manager and Qualified Person at Biomay. “With our proven expertise in allergen production and our stringent quality policy, we will further position ourselves as a first address for highly pure allergens in GMP quality.”

Bet v 1.0101 – the major birch pollen allergen – is the first offered GMP product. With Bet v 1, Biomay was the first company worldwide to clone and produce a recombinant pollen allergen. More than ever, recombinant Bet v 1 is of commercial and scientific interest in allergy research. This year, Biomay will add further products to the list of GMP allergens ready for immediate shipment. Prices will be disclosed on request.

More information:
http://www.biomay.com/products-services/recombinant-allergens.html

Contact:
info(at)biomay.com

(Vienna, February 11, 2009)